GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (OTCPK:GNNSF) » Definitions » Shares Outstanding (EOP)

Genscript Biotech (Genscript Biotech) Shares Outstanding (EOP) : 2,120.6 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Genscript Biotech Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Genscript Biotech's shares outstanding for the quarter that ended in Dec. 2023 was 2,120.6 Mil.

Genscript Biotech's quarterly shares outstanding increased from Jun. 2023 (2,116.0 Mil) to Dec. 2023 (2,120.6 Mil). It means Genscript Biotech issued new shares from Jun. 2023 to Dec. 2023 .

Genscript Biotech's annual shares outstanding increased from Dec. 2022 (2,111.2 Mil) to Dec. 2023 (2,120.6 Mil). It means Genscript Biotech issued new shares from Dec. 2022 to Dec. 2023 .


Genscript Biotech Shares Outstanding (EOP) Historical Data

The historical data trend for Genscript Biotech's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genscript Biotech Shares Outstanding (EOP) Chart

Genscript Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,878.38 1,953.28 2,095.69 2,111.23 2,120.62

Genscript Biotech Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,095.69 2,111.83 2,111.23 2,116.02 2,120.62

Competitive Comparison of Genscript Biotech's Shares Outstanding (EOP)

For the Biotechnology subindustry, Genscript Biotech's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genscript Biotech's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genscript Biotech's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Genscript Biotech's Shares Outstanding (EOP) falls into.



Genscript Biotech Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Genscript Biotech  (OTCPK:GNNSF) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Genscript Biotech Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Genscript Biotech's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Genscript Biotech (Genscript Biotech) Business Description

Traded in Other Exchanges
Address
No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100
GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.

Genscript Biotech (Genscript Biotech) Headlines